Seeking Alpha

Dan Jacome » Comments » Single Comment |

  • Pfizer: A Case Study of the Market's Extremely Low Valuations [View article]

    Generics typically chop off 80% off a branded drugs revenue base - market is smarter than all of us and pricing in Armageddon for Pfizer and that explains the ugly chart above. A low P/E means nothing in this market - PFE will only be bought by value long PMs if there is a tangible catalyst in the future for Pfizer - and sadly, there isn't one last time I checked. Add to this the threat from Obama that he wants the US govt to negotiate drug prices with Big Pharma on behalf of Medicare and viola - you land at PFEs battered share price. Likely washed out down here, but this is slow moving money for a while
    Jan 01 20:57 pm |Rating: +1 0
All Comments by Dan Jacome »
Comments by Ticker
AA, AAPL, ABC, ABMD, ABT, ABWTQ.PK, ABX, ACAD, ACHN, ACI, ACLS, ACMR, ACN, ACS, ACXM, ADBL, ADCT, ADLR, ADM, ADP, ADSK, ADY, AEM, AEO, AET, AFAM, AFFM, AFFX, AFL, AGN, AGU, AHBIF.PK, AHL, AIB, AIG, AINV, AIXG, AKAM, AKS, ALB, ALD, ALGT, ALKS, ALL, ALO, ALU, ALVR, AMAG, AMAT, AMD,
Dan Jacome's
Comments Stats
683 comments
Rating: 67 (91 - 24 )